Santhera Pharmaceuticals (OTCMKTS:SPHDF)‘s stock had its “neutral” rating reaffirmed by analysts at Credit Suisse Group in a report issued on Wednesday, The Fly reports.
Santhera Pharmaceuticals stock remained flat at $$2.75 during midday trading on Wednesday. Santhera Pharmaceuticals has a 12-month low of $2.62 and a 12-month high of $10.00. The stock has a 50 day moving average of $2.98 and a 200-day moving average of $3.34.
Santhera Pharmaceuticals Company Profile
Featured Article: Trading signals using Bollinger bands
Receive News & Ratings for Santhera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santhera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.